Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates

Advanced Drug Delivery Reviews

Volumn 102, Issue , 2016, Pages 73-82

  Agger, Else Marie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

BCG boost vaccine; Delivery systems; Dual component adjuvants; Immunomodulators; Long term memory; Mucosal adjuvants; PAMPs; Tuberculosis

Indexed keywords

HEALTH RISKS; IMMUNE SYSTEM; PROTEINS; RECOMBINANT PROTEINS;

DELIVERY SYSTEMS; DUAL-COMPONENT ADJUVANTS; IMMUNOMODULATORS; LONG TERM MEMORY; MUCOSAL ADJUVANTS; PAMPS; TUBERCULOSIS;

VACCINES;

BCG VACCINE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LIGAND; PATHOGEN ASSOCIATED MOLECULAR PATTERN; TOLL LIKE RECEPTOR;

BCG VACCINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNOLOGICAL MEMORY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL; MYCOBACTERIUM TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; DRUG COMPOUNDING; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84969498401     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.11.012     Document Type: Review

References (118)

1. WHO Global Tuberculosis Report 2014.
2. Shann F. Commentary: BCG vaccination halves neonatal mortality. Pediatr. Infect. Dis. J. 2012, 31:308-309.
3. Frick M. The tuberculosis vaccines pipeline: a new path to the same destination?. HIV, HCV & TB Pipeline Report 2015, Treatment Action Group.
4. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., Baehner F., Borkowski A., Tsai T.F., Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 2011, 365:1406-1416.
5. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., Lingnau K., von Gabain A., Andersen C.S., Korsholm K.S., Andersen P. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006, 24:5452-5460.
6. Orme I.M. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J. Immunol. 1988, 140:3589-3593.
7. Muller I., Cobbold S.P., Waldmann H., Kaufmann S.H. Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect. Immun. 1987, 55:2037-2041.
8. Holten-Andersen L., Doherty T.M., Korsholm K.S., Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 2004, 72:1608-1617.
9. Freidag B.L., Melton G.B., Collins F., Klinman D.M., Cheever A., Stobie L., Suen W., Seder R.A. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. 2000, 68:2948-2953.
10. Orme I.M., Robinson R.T., Cooper A.M. The balance between protective and pathogenic immune responses in the TB-infected lung. Nat. Immunol. 2015, 16:57-63.
11. Andersen P., Urdahl K.B. TB vaccines: promoting rapid and durable protection in the lung. Curr. Opin. Immunol. 2015, 35:55-62.
12. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., Schreiber R., Mak T.W., Bloom B.R. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
13. Feng C.G., Britton W.J. CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guerin. J. Infect. Dis. 2000, 181:1846-1849.
14. Behar S.M., Woodworth J.S., Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev. Vaccines 2007, 6:441-456.
15. Gopal R., Monin L., Slight S., Uche U., Blanchard E., Fallert Junecko B.A., Ramos-Payan R., Stallings C.L., Reinhart T.A., Kolls J.K., Kaushal D., Nagarajan U., Rangel-Moreno J., Khader S.A. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog. 2014, 10:e1004099.
16. Wozniak T.M., Saunders B.M., Ryan A.A., Britton W.J. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect. Immun. 2010, 78:4187-4194.
17. Monin L., Griffiths K.L., Slight S., Lin Y., Rangel-Moreno J., Khader S.A. Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge. Mucosal Immunol. 2015, 8:1099-1109.
18. Orr M.T., Windish H.P., Beebe E.A., Argilla D., Huang P.W., Reese V.A., Reed S.G., Coler R.N. Interferon gamma and tumor necrosis factor are not essential parameters of CD4+ T-cell responses for vaccine control of tuberculosis. J. Infect. Dis. 2015, 212:495-504.
19. Khader S.A., Pearl J.E., Sakamoto K., Gilmartin L., Bell G.K., Jelley-Gibbs D.M., Ghilardi N., deSauvage F., Cooper A.M. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J. Immunol. 2005, 175:788-795.
20. Ribi E., Granger D.L., Milner K.C., Yamamoto K., Strain S.M., Parker R., Smith R.W., Brehmer W., Azuma I. Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials. Immunology 1982, 46:297-305.
21. Ribi E., Larson C., Wicht W., List R., Goode G. Effective nonliving vaccine against experimental tuberculosis in mice. J. Bacteriol. 1966, 91:975-983.
22. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 1994, 62:2536-2544.
23. Bosio C.M., Orme I.M. Effective, nonsensitizing vaccination with culture filtrate proteins against virulent Mycobacterium bovis infections in mice. Infect. Immun. 1998, 66:5048-5051.
24. Brandt L., Elhay M.J., Rosenkrands I., Lindblad E.B., Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 2000, 68:791-795.
25. Maisonneuve C., Bertholet S., Philpott D.J., De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:12294-12299.
26. Killick K.E., Ni Cheallaigh C., O'Farrelly C., Hokamp K., MacHugh D.E., Harris J. Receptor-mediated recognition of mycobacterial pathogens. Cell. Microbiol. 2013, 15:1484-1495.
27. Ribi E., Meyer T.J., Azuma I., Parker R., Brehmer W. Biologically active components from mycobacterial cell walls. IV. Protection of mice against aerosol infection with virulent mycobacterium tuberculosis. Cell. Immunol. 1975, 16:1-10.
28. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D.J., Sansonetti P.J. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003, 278:8869-8872.
29. Yang Y., Yin C., Pandey A., Abbott D., Sassetti C., Kelliher M.A. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J. Biol. Chem. 2007, 282:36223-36229.
30. Werninghaus K., Babiak A., Gross O., Holscher C., Dietrich H., Agger E.M., Mages J., Mocsai A., Schoenen H., Finger K., Nimmerjahn F., Brown G.D., Kirschning C., Heit A., Andersen P., Wagner H., Ruland J., Lang R. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J. Exp. Med. 2009, 206:89-97.
31. Bekierkunst A., Levij I.S., Yarkoni E., Vilkas E., Adam A., Lederer E. Granuloma formation induced in mice by chemically defined mycobacterial fractions. J. Bacteriol. 1969, 100:95-102.
32. Pimm M.V., Baldwin R.W., Polonsky J., Lederer E. Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6'-dimycolate) and synthetic analogues. Int. J. Cancer 1979, 24:780-785.
33. Parant M., Audibert F., Parant F., Chedid L., Soler E., Polonsky J., Lederer E. Nonspecific immunostimulant activities of synthetic trehalose-6,6'-diesters (lower homologs of cord factor). Infect. Immun. 1978, 20:12-19.
34. Olsen A.W., Pinxteren L.A.H.v., Okkels L., Andersen R.P.B.P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect. Immun. 2001, 69:2773-2778.
35. Olsen A.W., Williams A., Okkels L.M., Hatch G., Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 2004, 72:6148-6150.
36. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., Agger E.M., Andersen P. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 2005, 1718:22-31.
37. Lindenstrom T., Agger E.M., Andersen P. Control of chronic M. tuberculosis infection by CD4 KLRG1-IL-2 secreting memory cells. J. Immunol. 2013, 190:6311-6319.
38. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 2009, 182:8047-8055.
39. van Dissel J.T., Joosten S.A., Hoff S.T., Soonawala D., Prins C., Hokey D.A., O'Dee D.M., Graves A., Thierry-Carstensen B., Andreasen L.V., Ruhwald M., de Visser A.W., Agger E.M., Ottenhoff T.H., Kromann I., Andersen P. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 2014, 32:7098-7107.
40. Ishikawa E., Ishikawa T., Morita Y.S., Toyonaga K., Yamada H., Takeuchi O., Kinoshita T., Akira S., Yoshikai Y., Yamasaki S. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 2009, 206:2879-2888.
41. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., Agger E.M., Stenger S., Andersen P., Ruland J., Brown G.D., Wells C., Lang R. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 2010, 184:2756-2760.
42. Miyake Y., Toyonaga K., Mori D., Kakuta S., Hoshino Y., Oyamada A., Yamada H., Ono K., Suyama M., Iwakura Y., Yoshikai Y., Yamasaki S. C-type lectin MCL is an FcRgamma-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 2013, 38:1050-1062.
43. Ostrop J., Jozefowski K., Zimmermann S., Hofmann K., Strasser E., Lepenies B., Lang R. Contribution of MINCLE-SYK Signaling to activation of primary human APCs by mycobacterial cord factor and the novel adjuvant TDB. J. Immunol. 2015, 195:2417-2428.
44. Denis M., Ainge G.D., Larsen D.S., Severn W.B., Painter G.F. A synthetic analogue of phosphatidylinositol mannoside is an efficient adjuvant. Immunopharmacol. Immunotoxicol. 2009, 31:577-582.
45. Sprott G.D., Dicaire C.J., Gurnani K., Sad S., Krishnan L. Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette-Guerin and adjuvant activity in vivo. Infect. Immun. 2004, 72:5235-5246.
46. Parlane N.A., Compton B.J., Hayman C.M., Painter G.F., Basaraba R.J., Heiser A., Buddle B.M. Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection. Vaccine 2012, 30:580-588.
47. Layre E., Collmann A., Bastian M., Mariotti S., Czaplicki J., Prandi J., Mori L., Stenger S., De Libero G., Puzo G., Gilleron M. Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. Chem. Biol. 2009, 16:82-92.
48. Andersen C.S., Agger E.M., Rosenkrands I., Gomes J.M., Bhowruth V., Gibson K.J., Petersen R.V., Minnikin D.E., Besra G.S., Andersen P. A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J. Immunol. 2009, 182:424-432.
49. Hattori Y., Morita D., Fujiwara N., Mori D., Nakamura T., Harashima H., Yamasaki S., Sugita M. Glycerol monomycolate is a novel ligand for the human, but not mouse macrophage inducible C-type lectin, Mincle. J. Biol. Chem. 2014, 289:15405-15412.
50. Mortaz E., Adcock I.M., Tabarsi P., Masjedi M.R., Mansouri D., Velayati A.A., Casanova J.L., Barnes P.J. Interaction of pattern recognition receptors with Mycobacterium tuberculosis. J. Clin. Immunol. 2015, 35:110.
51. Cooper A.M., Roberts A.D., Rhoades E.R., Callahan J.E., Getzy D.M., Orme I.M. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995, 84:423-432.
52. Ballester M., Nembrini C., Dhar N., de Titta A., de Piano C., Pasquier M., Simeoni E., van der Vlies A.J., McKinney J.D., Hubbell J.A., Swartz M.A. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011, 29:6959-6966.
53. Fonseca D.M., Silva C.L., Paula M.O., Soares E.G., Marchal G., Horn C., Bonato V.L. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 2007, 121:508-517.
54. Geluk A., van den Eeden S.J., van Meijgaarden K.E., Dijkman K., Franken K.L., Ottenhoff T.H. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice. Vaccine 2012, 30:7513-7521.
55. Coppola M., van den Eeden S.J., Wilson L., Franken K.L., Ottenhoff T.H., Geluk A. Synthetic long peptide derived from Mycobacterium tuberculosis latency antigen Rv1733c protects against tuberculosis. Clin. Vaccine Immunol. 2015, 22:1060-1069.
56. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., Swatosch G., Zauner W., Kast C., Akira S., von Gabain A., Buschle M., Lingnau K. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24:5461-5472.
57. Lin P.L., Dietrich J., Tan E., Abalos R.M., Burgos J., Bigbee C., Bigbee M., Milk L., Gideon H.P., Rodgers M., Cochran C., Guinn K.M., Sherman D.R., Klein E., Janssen C., Flynn J.L., Andersen P. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 2012, 122:303-314.
58. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., Tingskov P.N., Lingnau K., Nouta J., Hoff S.T., Rosenkrands I., Kromann I., Ottenhoff T.H., Doherty T.M., Andersen P. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
59. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., Nouta J., Klein M.R., Rosenkrands I., Ottenhoff T.H., Kromann I., Doherty T.M., Andersen P. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571-3581.
60. 3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS One 2014, 9:e114602.
61. Lenz N., Schindler T., Kagina B.M., Zhang J.D., Lukindo T., Mpina M., Bang P., Kromann I., Hoff S.T., Andersen P., Reither K., Churchyard G.J., Certa U., Daubenberger C.A. Antiviral innate immune activation in HIV-infected adults negatively affects H1/IC31-induced vaccine-specific memory CD4+ T Cells. Clin. Vaccine Immunol. 2015, 22:688-696.
62. Geldenhuys H., Mearns H., Miles D.J., Tameris M., Hokey D., Shi Z., Bennett S., Andersen P., Kromann I., Hoff S.T., Hanekom W.A., Mahomed H., Hatherill M., Scriba T.J., Group H.I.T.S., van Rooyen M., Bruce McClain J., Ryall R., de Bruyn G., Groupa H.I.T.S. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial. Vaccine 2015, 33:3592-3599.
63. Luabeya A.K., Kagina B.M., Tameris M.D., Geldenhuys H., Hoff S.T., Shi Z., Kromann I., Hatherill M., Mahomed H., Hanekom W.A., Andersen P., Scriba T.J., Group H.T.S., Schoeman E., Krohn C., Day C.L., Africa H., Makhethe L., Smit E., Brown Y., Suliman S., Hughes E.J., Bang P., Snowden M.A., McClain B., Hussey G.D. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 2015, 33:4130-4140.
64. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., Bosio C., Dow S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 2006, 176:7335-7345.
65. Wedlock D.N., Denis M., Painter G.F., Ainge G.D., Vordermeier H.M., Hewinson R.G., Buddle B.M. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. CVI 2008, 15:765-772.
66. Verwaerde C., Debrie A.S., Dombu C., Legrand D., Raze D., Lecher S., Betbeder D., Locht C. HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis. Vaccine 2014, 32:6240-6250.
67. Shen H., Tesar B.M., Walker W.E., Goldstein D.R. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 2008, 181:1849-1858.
68. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 2011, 10:471-486.
69. Penn-Nicholson A., Geldenhuys H., Burny W., van der Most R., Day C.L., Jongert E., Moris P., Hatherill M., Ofori-Anyinam O., Hanekom W., Vaccine Study T., Bollaerts A., Demoitie M.A., Kany Luabeya A.K., De Ruymaeker E., Tameris M., Lapierre D., Scriba T.J. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 2015, 33:4025-4034.
70. Day C.L., Tameris M., Mansoor N., van Rooyen M., de Kock M., Geldenhuys H., Erasmus M., Makhethe L., Hughes E.J., Gelderbloem S., Bollaerts A., Bourguignon P., Cohen J., Demoitie M.A., Mettens P., Moris P., Sadoff J.C., Hawkridge A., Hussey G.D., Mahomed H., Ofori-Anyinam O., Hanekom W.A. Induction and regulation of T cell immunity by the novel TB vaccine M72/AS01 in South African adults. Am. J. Respir. Crit. Care Med. 2013, 188:492-502.
71. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., Laughlin E.M., Duthie M.S., Fox C.B., Carter D., Friede M., Vedvick T.S., Reed S.G. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
72. Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 2012, 188:2189-2197.
73. Coler R.N., Bertholet S., Pine S.O., Orr M.T., Reese V., Windish H.P., Davis C., Kahn M., Baldwin S.L., Reed S.G. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J. Infect. Dis. 2012, 207:1242-1252.
74. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5:505-517.
75. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9:287-293.
76. Orr M.T., Fox C.B., Baldwin S.L., Sivananthan S.J., Lucas E., Lin S., Phan T., Moon J.J., Vedvick T.S., Reed S.G., Coler R.N. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J. Control. Release 2013, 172:190-200.
77. Hussain M.J., Wilkinson A., Bramwell V.W., Christensen D., Perrie Y. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants. J. Pharm. Pharmacol. 2014, 66:358-366.
78. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., Campos-Neto A., Lobet Y., Dalemans W., Orme I.M., Reed S.G. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 2004, 172:7618-7628.
79. Leroux-Roels I., Forgus S., De Boever F., Clement F., Demoitie M.A., Mettens P., Moris P., Ledent E., Leroux-Roels G., Ofori-Anyinam O., The M.S.G. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2012, 31:2196-2206.
80. Roberts A.D., Sonnenberg M.G., Ordway D.J., Furney S.K., Brennan P.J., Belisle J.T., Orme I.M. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 1995, 85:502-508.
81. Henriksen-Lacey M., Christensen D., Bramwell V.W., Lindenstrom T., Agger E.M., Andersen P., Perrie Y. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J. Control. Release 2010, 145:102-108.
82. Henriksen-Lacey M., Bramwell V.W., Christensen D., Agger E.M., Andersen P., Perrie Y. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control. Release 2010, 142:180-186.
83. Korsholm K.S., Agger E.M., Foged C., Christensen D., Dietrich J., Andersen C.S., Geisler C., Andersen P. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007, 121:216-226.
84. Christensen D., Henriksen-Lacey M., Kamath A.T., Lindenstrom T., Korsholm K.S., Christensen J.P., Rochat A.F., Lambert P.H., Andersen P., Siegrist C.A., Perrie Y., Agger E.M. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J. Control. Release 2012, 160:468-476.
85. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
86. Vogelzang A., Perdomo C., Zedler U., Kuhlmann S., Hurwitz R., Gengenbacher M., Kaufmann S.H. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guerin DeltaureC::hly vaccine's superior protection against tuberculosis. J. Infect. Dis. 2014, 210:1928-1937.
87. Orme I.M. The Achilles heel of BCG. Tuberculosis (Edinb.) 2010, 90:329-332.
88. Horscroft N.J., Pryde D.C., Bright H. Antiviral applications of Toll-like receptor agonists. J. Antimicrob. Chemother. 2012, 67:789-801.
89. Kamath A.T., Valenti M.P., Rochat A.F., Agger E.M., Lingnau K., von Gabain A., Andersen P., Lambert P.H., Siegrist C.A. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur. J. Immunol. 2008, 38:1247-1256.
90. Aichinger M.C., Ginzler M., Weghuber J., Zimmermann L., Riedl K., Schutz G., Nagy E., von Gabain A., Schweyen R., Henics T. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine 2011, 29:426-436.
91. Kamath A.T., Rochat A.F., Christensen D., Agger E.M., Andersen P., Lambert P.H., Siegrist C.A. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS One 2009, 4:e5771.
92. Wu T.Y., Singh M., Miller A.T., De Gregorio E., Doro F., D'Oro U., Skibinski D.A., Mbow M.L., Bufali S., Herman A.E., Cortez A., Li Y., Nayak B.P., Tritto E., Filippi C.M., Otten G.R., Brito L.A., Monaci E., Li C., Aprea S., Valentini S., Calabromicron S., Laera D., Brunelli B., Caproni E., Malyala P., Panchal R.G., Warren T.K., Bavari S., O'Hagan D.T., Cooke M.P., Valiante N.M. Rational design of small molecules as vaccine adjuvants. Sci. Transl. Med. 2014, 6:263ra160.
93. Primard C., Poecheim J., Heuking S., Sublet E., Esmaeili F., Borchard G. Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization. Mol. Pharm. 2013, 10:2996-3004.
94. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., Lambeck A.J., Figdor C.G. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118:6836-6844.
95. Aeras http://www.aeras.org/candidates#preclinical.
96. Tyne A.S., Chan J.G., Shanahan E.R., Atmosukarto I., Chan H.K., Britton W.J., West N.P. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine 2013, 31:4322-4329.
97. Spencer A.J., Hill F., Honeycutt J.D., Cottingham M.G., Bregu M., Rollier C.S., Furze J., Draper S.J., Sogaard K.C., Gilbert S.C., Wyllie D.H., Hill A.V. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One 2012, 7:e33555.
98. Kita Y., Hashimoto S., Nakajima T., Nakatani H., Nishimatsu S., Nishida Y., Kanamaru N., Kaneda Y., Takamori Y., McMurray D., Tan E.V., Cang M.L., Saunderson P., Dela Cruz E.C., Okada M. Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy. Hum. Vaccin. Immunother. 2013, 9:526-533.
99. Okada M., Kita Y., Nakajima T., Kanamaru N., Hashimoto S., Nagasawa T., Kaneda Y., Yoshida S., Nishida Y., Nakatani H., Takao K., Kishigami C., Inoue Y., Matsumoto M., McMurray D.N., Dela Cruz E.C., Tan E.V., Abalos R.M., Burgos J.A., Saunderson P., Sakatani M. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009, 27:3267-3270.
100. Hwang S.A., Welsh K.J., Boyd S., Kruzel M.L., Actor J.K. Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen. Tuberculosis (Edinb.) 2011, 91(Suppl. 1):S90-S95.
101. Venkataswamy M.M., Baena A., Goldberg M.F., Bricard G., Im J.S., Chan J., Reddington F., Besra G.S., Jacobs W.R., Porcelli S.A. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 2009, 183:1644-1656.
102. Derrick S.C., Dao D., Yang A., Kolibab K., Jacobs W.R., Morris S.L. Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis. PLoS One 2012, 7:e32959.
103. Dietrich J., Billeskov R., Doherty T.M., Andersen P. Synergistic effect of Bacillus Calmette Guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J. Immunol. 2007, 178:3721-3730.
104. White A.D., Sibley L., Dennis M.J., Gooch K., Betts G., Edwards N., Reyes-Sandoval A., Carroll M.W., Williams A., Marsh P.D., McShane H., Sharpe S.A. An evaluation of the safety and immunogenicity of a candidate TB vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin. Vaccine Immunol. 2013, 20:663-672.
105. Doherty T.M., Olsen A.W., van Pinxteren L., Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 2002, 70:3111-3121.
106. Todoroff J., Lemaire M.M., Fillee C., Jurion F., Renauld J.C., Huygen K., Vanbever R. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS One 2013, 8:e63344.
107. Turner D.L., Bickham K.L., Thome J.J., Kim C.Y., D'Ovidio F., Wherry E.J., Farber D.L. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 2014, 7:501-510.
108. Sakai S., Kauffman K.D., Schenkel J.M., McBerry C.C., Mayer-Barber K.D., Masopust D., Barber D.L. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J. Immunol. 2014, 192:2965-2969.
109. Connor L.M., Harvie M.C., Rich F.J., Quinn K.M., Brinkmann V., Le Gros G., Kirman J.R. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur. J. Immunol. 2010, 40:2482-2492.
110. Griffiths K.L., Stylianou E., Poyntz H.C., Betts G.J., Fletcher H.A., McShane H. Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice. PLoS One 2013, 8:e78312.
111. Lee J.B., Jang J.E., Song M.K., Chang J. Intranasal delivery of cholera toxin induces Th17-dominated T-cell response to bystander antigens. PLoS One 2009, 4:e5190.
112. Gopal R., Rangel-Moreno J., Slight S., Lin Y., Nawar H.F., Fallert Junecko B.A., Reinhart T.A., Kolls J., Randall T.D., Connell T.D., Khader S.A. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 2013, 6:972-984.
113. Dietrich J., Andersen C., Rappuoli R., Doherty T.M., Jensen C.G., Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J. Immunol. 2006, 177:6353-6360.
114. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., Woodrow M., Thierry-Carstensen B., Andersen P., Novicki D., Del Giudice G., Rappuoli R. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4:e6999.
115. Stylianou E., Diogo G.R., Pepponi I., van Dolleweerd C., Arias M.A., Locht C., Rider C.C., Sibley L., Cutting S.M., Loxley A., Ma J.K., Reljic R. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur. J. Immunol. 2014, 44:440-449.
116. Huang J.M., Hong H.A., Van Tong H., Hoang T.H., Brisson A., Cutting S.M. Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 2010, 28:1021-1030.
117. Reljic R., Sibley L., Huang J.M., Pepponi I., Hoppe A., Hong H.A., Cutting S.M. Mucosal vaccination against tuberculosis using inert bioparticles. Infect. Immun. 2013, 81:4071-4080.
118. Orr M.T., Beebe E.A., Hudson T.E., Moon J.J., Fox C.B., Reed S.G., Coler R.N. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 2014, 9:e83884.